<DOC>
	<DOCNO>NCT01181284</DOCNO>
	<brief_summary>Patients pulmonary arterial hypertension ( PAH ) suffer chronic shortness breath , impaired survival relate progressive right ventricular failure . Abnormal vasoreactivity nitric oxide ( NO ) play role pathophysiology PAH . Phosphodiesterase Type 5 Inhibitor ( PDE5 inhibitor ) sildenafil show beneficial PAH , extent benefit variable .</brief_summary>
	<brief_title>Modulating Effects Lisinopril Sildenafil Activity Pulmonary Arterial Hypertension ( PAH ) ( MELISSA )</brief_title>
	<detailed_description>The broad aim investigation determine whether modulate effect angiotensin convert enzyme inhibition vascular smooth muscle responsiveness nitric oxide pathway observe animal model Congestive Heart Failure ( CHF ) exploit human PAH . Furthermore , identify group gene TAO kinase I , IL-10 , Rho kinase , Raf1 , bile acid coenzyme A Fmr1 modulate long-acting angiotensin-converting enzyme inhibitor ( ACEI ) animal model , therefore may also modulate ACEI patient PAH</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Age 1875 World Health Organization ( WHO ) Group I PAH prior documentation peripheral vascular resistance ( PVR ) &gt; 3 WU wedge ( PCW ) 16 less . WHO Functional Class IIII 6 minute walk distance 150575 meter Women child bear potential must negative pregnancy test use effective contraception Receiving therapy phosphodiesterase5 inhibitor PAH ( sildenafil tadalafil ) least 3 month stable dose least 30 day If already receive therapy endothelin receptor antagonist must therapy least 3 month stable dose least 30 day Allergy intolerance captopril angiotensin convert enzyme inhibitor Systemic systolic blood pressure le 100 mm Hg Therapy prostanoids ( iloprost , treprostinil , epoprostenol ) within precede 3 month Pregnant breast feed Creatinine &gt; 2.0 mg/dl Potassium &gt; 5.0 meq/dl Unable provide inform consent TLC VC &lt; 60 % predict Untreated obstructive sleep apnea LVEF &lt; 40 % Hb &lt; 10 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH )</keyword>
</DOC>